BD Q2 revenue $5.0B (+4.6%), adj. EPS $3.17 (+10.8%); raises FY24 adjusted EPS guidance

BECTON DICKINSON & CO

2024-Q2 EPS reported $2.81 revenue$9,751,000,000

Q2 revenue $5,045M (+4.6% reported, +5.7% organic); GAAP diluted EPS $1.85 (+20.9%), adjusted EPS $3.17 (+10.8%).
Year-to-date Cash from Ops $1.4B; Free Cash Flow $1.1B, up >$900M YoY.
Company raises full-year adjusted EPS guidance and affirms organic revenue growth forecast.
BD Medical increasing domestic syringe production after FDA safety communication on non-BD syringes.
BD Life Sciences launched three- and four-laser additions to BD FACSDiscover S8 Cell Sorter family.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BECTON DICKINSON & CO updated its its second quarter of fiscal 2024, which ended March 31, 2024 guidance (raised).

Period: its second quarter of fiscal 2024, which ended March 31, 2024
Guidance: raised
Result: reported results

Exact text from the filing

On May 2, 2024, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2024.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

BECTON DICKINSON & CO filing history →

Source: SEC EDGAR

accession 0000010795-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.